Scoring Algorithm to Predict Survival after Nephrectomy and Immunotherapy in Patients with Metastatic Renal Cell Carcinoma: A Stratification Tool for Prospective Clinical Trials

Cancer

Volumn 98, Issue 12, 2003, Pages 2566-2575

  Leibovich, Bradley C ^a,b   Han, Ken Ryu ^a   Bui, Matthew H T ^a   Pantuck, Allan J ^a   Dorey, Frederick J ^a   Figlin, Robert A ^a   Belldegrun, Arie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Kidney neoplasms; Metastasis; Renal cell carcinoma; Survival

Indexed keywords

RECOMBINANT INTERLEUKIN 2; THYROTROPIN;

ADRENALECTOMY; ADULT; AGE; AGED; ALGORITHM; ARTICLE; BLOOD TRANSFUSION; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; GENDER; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOTHERAPY; KIDNEY CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SYMPTOMATOLOGY; THYROTROPIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGED; ALGORITHMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0345098465     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11851     Document Type: Article

References (48)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. Ca Cancer J Clin. 2002;52:23-47.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
3. Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF Jr. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990;1:133-141.
4. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol. 1999;161:381-386.
5. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
6. Mickisch GH, Garin A, van Poppel H, et al. for the European Organisation for Research and Treatment of Cancer. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
7. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001;345:1711-1712.
8. Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:981-986.
9. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific surviral. J Urol. 2001;166:453-456.
10. Igarashi T, Tobe T, Nakatsu HO, et al. The impact of a 4 cm. cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol. 2001;165:1103-1106.
11. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol. 1999;162:1277-1281.
12. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35-40.
13. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
14. Papadopoulos I, Rudolph P, Weichert-Jacobsen K, Thiemann O, Papadopoulou D. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine. Urology. 1996;48:373-378.
15. Srigley JR, Hutter RV, Gelb AB, et al. Current prognostic factors - renal cell carcinoma: Workgroup no. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:994-996.
16. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163:1090-1095.
17. van Bezooijen RL, Goey H, Stoter G, Hermans J, Fleuren GJ. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2. Cancer Immunol Immunother. 1996;43:293-298.
18. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J Clin Oncol. 2001;19:3792-3793.
19. Zisman A, Pantuck AJ, Dorey F, et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20:1368-1374.
20. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314-319.
21. Fuhrman S, Lasky C, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
22. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup no. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992-993.
23. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:987-989.
24. Zisman A, Pantuck AJ, Chao D, et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001;166:54-58.
25. Frank I, Blute ML, Weaver AL, Zincke H. TNM staging alone is inadequate for predicting cancer-specific survival following radical nephrectomy for unilateral renal cell carcinoma. J Urol. 2001;165:768A.
26. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
27. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol. 1990;144(2 Pt 1):238-241.
28. Targonski PV, Frank W, Stuhldreher D, Guinan PD, Value of tumor size in predicting survival from renal cell carcinoma among tumors, nodes and metastases Stage 1 and Stage 2 patients. J Urol. 1994;152(5 Pt 1):1389-1392.
29. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer. 2003;97:1663-1671.
30. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res. 1999;19:1573-1578.
31. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68-72.
32. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma? J Urol. 1991;146:1224-1227.
33. Kanamaru H, Mori H, Sasaki M, et al. Histologic characteristics of renal cell carcinomas with lymph node metastasis. Int J Urol. 1997;4:451-455.
34. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163:426-430.
35. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
36. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol. 2000;34:246-251.
37. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol. 1986;136:376-379.
38. Kankuri M, Pelliniemi TT, Pyrhonen S, Nikkanen V, Helenius H, Salminen E. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a Phase II study. Cancer. 2001;92:761-767.
39. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291.
40. Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K. Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int. 1999;83:222-226.
41. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604-614.
42. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528.
43. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha. J Immunother. 1991;10:448-455.
44. Vassilopolou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res. 1992;24:434-438.
45. Weijl NI, Van der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993;11:1376-1383.
46. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988;48(24 Pt 1):7310-7313.
47. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.
48. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.